Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Board Changes and Corporate Update

1 Apr 2016 12:44

RNS Number : 9216T
West African Minerals Corporation
01 April 2016
 

For immediate release

1 April 2016

West African Minerals Corporation

("West African" or the "Company")

 

Board changes and corporate update

 

The Board of the Company announces that on 31 March 2016, Brad Mills informed the Company that he had resigned as Chairman of the Board of the Company with immediate effect. Gerard Holden, an existing Non-Executive Director, has been appointed Chairman. Brad Mills will remain as a Non-Executive Director of the Company.

 

The Board of the Company is now as follows:

 

Gerard Holden

Chairman

James Mellon

Non-Executive Director

Andrew Gutmann

Non-Executive Director

Willy Simon

Non-Executive Director

Brad Mills

Non-Executive Director

 

As previously announced on 27 February 2015, the Company had appointed Plinian Capital Limited as operator of the Company's Cameroon projects at a total annual cost of US$160,000 (equivalent to approximately £103,000) for an initial term of 12 months ("Operator Agreement"). Brad Mills, who is also the controlling shareholder of Plinian Capital Limited, informed the Company yesterday that the Operator Agreement would also terminate with effect from 31 March 2016.

 

For further information contact:

West African Minerals Corporation

Gerard Holden

 

+44 (0) 7785 503 593

 

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish

Michael Cornish

 

+44 (0)20 7628 3396

SP Angel Corporate Finance LLP (Broker)

Ewan Leggat

 

+44 (0) 20 3470 0500

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFSLSFILIIR
Date   Source Headline
7th Sep 20221:30 pmRNSResult of AGM
30th Aug 20227:00 amRNSQ4 '22 IND planned followed by P2 with AmbioPharm
19th Aug 20227:00 amRNSNotice of AGM
18th Aug 20222:06 pmRNSSecond Price Monitoring Extn
18th Aug 20222:00 pmRNSPrice Monitoring Extension
16th Aug 20227:00 amRNSAnnual Financial Report
9th Jun 20227:08 amRNSDirector/PDMR Shareholding
20th May 20227:00 amRNSDirector/PDMR Shareholding
19th May 20224:01 pmRNSClosing of Offering
18th May 202210:10 amRNSDirector/PDMR Shareholding
17th May 20227:00 amRNSOKYO Announces Pricing of IPO of ADSs in the U.S.
27th Apr 20227:00 amRNSUpcoming Presentations at Ophthalmic Conference
7th Mar 20227:00 amRNSAdditional Listing
23rd Feb 20227:00 amRNSPatent issued: to treat ocular neuropathic pain
21st Feb 20225:00 pmRNSCLN Conversion, exercise of Warrants, equity issue
15th Feb 20227:00 amRNSSuccessful Pre-IND Meeting with the FDA on OK-101
1st Feb 20227:00 amRNSDirector/PDMR Shareholding
27th Jan 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20222:05 pmRNSSecond Price Monitoring Extn
26th Jan 20222:00 pmRNSPrice Monitoring Extension
26th Jan 20227:00 amRNSHalf-year Report
14th Dec 20217:00 amRNSU.S. Patent issued for use of OK-101 to treat DED
13th Dec 20217:00 amRNSOK-101:Anti-inflammatory & Pain-Reducing Potential
6th Dec 20217:00 amRNSIND filing Q3 2022 and Phase 2 initiation Q4 2022
1st Dec 20217:00 amRNSDirectorate Change
19th Oct 20214:41 pmRNSSecond Price Monitoring Extn
19th Oct 20214:35 pmRNSPrice Monitoring Extension
19th Oct 20212:05 pmRNSSecond Price Monitoring Extn
19th Oct 20212:00 pmRNSPrice Monitoring Extension
27th Sep 202112:06 pmRNSResult of AGM
9th Sep 20217:00 amRNSNotice of AGM
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
2nd Aug 202111:32 amRNSAnnual Financial Report
29th Jun 20217:00 amRNSResearch Update
17th Jun 20213:58 pmRNSDirectorate Change
12th May 20217:00 amRNSHolding(s) in Company
7th May 202110:07 amRNSAdditional Listing
5th May 202111:53 amRNSPublication of a Prospectus
28th Apr 20217:00 amRNSPositive Data in an Animal Model using OK-201
29th Mar 20217:00 amRNSAppointment of Chief Scientific Officer
3rd Mar 20217:00 amRNSIssue of Equity
1st Mar 20217:00 amRNSIssue of Equity
23rd Feb 20217:00 amRNSPatent for treating Ocular Pain and Inflammation
19th Jan 20217:00 amRNSFiling patent application for the use of Chemerin
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:37 pmRNSPrice Monitoring Extension
14th Jan 20212:05 pmRNSSecond Price Monitoring Extn
14th Jan 20212:00 pmRNSPrice Monitoring Extension
7th Jan 20217:00 amRNSDirectorate Change
30th Nov 20207:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.